Endoscopic colorectal stenting for malignant large bowel obstruction comparing to surgery

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter D.H. Kang
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors D.H. Kang1, H.W. Kim1, C.W. Choi1, S.B. Park1, S.J. Kim1, H.S. Nam1, H.H. Jang2, S.B. Lee2, S.H. Lee2, J.M. Park2
  • 1Pusan National University Yangsan Hospital, Yangsan, Republic of Korea, /
  • 2Pusan National University Yangsan Hospital, Yangsan-si, Republic of Korea, /


Colorectal cancer is one of the most common cancers worldwide. Large bowel obstruction caused by advanced colonic cancer occurs in 8-13% of colonic cancer patients. Endoscopic colorectal stenting have been used to manage large bowel obstruction as a palliative treatment or to initially decompress the colon as a bridge to definitive surgery. Especially, endoscopic colorectal stenting in malignant obstruction has been reported to have the advantages such as high successful primary anastomosis and low overall stoma rate as a bridge to surgery, shorter hospital stay and cost effectiveness. But recent studies reported that colorectal stenting was no more effective and safe compared to emergency surgery in clinical success rate and overall complication rate. Our goal of this study was to compare the clinical outcomes between operation after colorectal stenting and surgery only for curative purpose in patients with colorectal obstruction.